20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Arvinas Inc (ARVN) operates in the BIOTECHNOLOGY industry and is headquartered in New Haven, United States with about 246 employees. Its market capitalization is roughly $464 million. In the fiscal year ended 2025-12-31, ARVN reported $263M in revenue and ($81M) in net income.
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins.
Interactive charts & full statements → Open the ARVN valuation workbench →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $317M | $263M | $263M | $78M | $131M | $47M | $22M | $43M | $14M | $8M | $7M |
| Gross Profit | $305M | $257M | $263M | $78M | $131M | $47M | $22M | $43M | $14M | $8M | $7M |
| Gross Margin % | 96.4% | 98.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Income (EBIT) | ($14M) | ($115M) | ($250M) | ($402M) | ($263M) | ($195M) | ($125M) | ($52M) | ($44M) | ($25M) | ($16M) |
| Operating Margin % | -4.5% | -43.8% | -95.0% | -511.5% | -200.3% | -418.2% | -572.7% | -119.9% | -305.8% | -326.7% | -246.9% |
| Net Income | $9M | ($81M) | ($199M) | ($367M) | ($272M) | ($183M) | ($112M) | ($62M) | ($41M) | ($24M) | ($14M) |
| Net Margin % | 2.9% | -30.8% | -75.5% | -467.9% | -206.9% | -392.3% | -512.7% | -144.6% | -289.6% | -317.3% | -215.2% |
| EBITDA | $3M | ($75M) | ($192M) | ($360M) | ($255M) | ($189M) | ($121M) | ($49M) | ($43M) | ($24M) | ($14M) |
| Earnings Per Share (EPS) | $0.16 | $-1.24 | $-2.77 | $-6.62 | $-5.11 | $-3.66 | $-2.83 | $-1.89 | $-1.31 | $-1.16 | $-0.80 |
| Shares Outstanding (M) | 66M | 65M | 72M | 56M | 53M | 50M | 40M | 33M | 32M | 21M | 18M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $250M | $16M | $10M | $42M | $22M | $189M | $59M | $102M |
| Gross Profit | $241M | $14M | $8M | $42M | $22M | $189M | $59M | $102M |
| Gross Margin % | 96.4% | 93.0% | 87.4% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Income (EBIT) | $164M | ($63M) | ($72M) | ($44M) | ($72M) | $71M | ($58M) | ($60M) |
| Operating Margin % | 65.7% | -401.9% | -754.7% | -104.5% | -319.2% | 37.8% | -98.3% | -58.9% |
| Net Income | $169M | ($58M) | ($67M) | ($35M) | ($61M) | $83M | ($45M) | ($49M) |
| Net Margin % | 67.8% | -369.2% | -709.5% | -83.8% | -273.2% | 43.9% | -76.2% | -48.0% |
| EBITDA | $159M | ($56M) | ($66M) | ($34M) | ($60M) | $84M | ($44M) | ($48M) |
| Earnings Per Share (EPS) | $2.58 | $-0.90 | $-1.04 | $-0.48 | $-0.84 | $1.14 | $-0.63 | $-0.68 |
| Shares Outstanding (M) | 66M | 64M | 65M | 73M | 73M | 73M | 72M | 72M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($207M) | ($274M) | ($259M) | ($348M) | ($274M) | $559M | ($90M) | ($41M) | ($16M) | $5M | ($19M) |
| Capital Expenditures (CapEx) | $2M | $2M | $2M | $3M | $7M | $5M | $6M | $6M | $3M | $1M | $0M |
| Free Cash Flow (FCF) | ($209M) | ($276M) | ($261M) | ($351M) | ($280M) | $555M | ($96M) | ($47M) | ($19M) | $4M | ($20M) |
| FCF Margin % | -65.9% | -105.0% | -99.1% | -446.8% | -213.3% | 1187.8% | -441.3% | -109.1% | -132.3% | 54.1% | -295.5% |
| Dividends Paid | — | — | — | — | — | — | — | $3M | $60M | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($48M) | ($69M) | ($30M) | ($59M) | ($95M) | ($89M) | ($84M) | ($128M) |
| Capital Expenditures (CapEx) | $0M | $1M | $0M | $0M | $1M | $0M | $0M | $1M |
| Free Cash Flow (FCF) | ($48M) | ($70M) | ($31M) | ($59M) | ($97M) | ($89M) | ($84M) | ($129M) |
| FCF Margin % | -19.4% | -451.9% | -322.1% | -141.3% | -431.2% | -47.3% | -142.6% | -125.7% |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $675M | $718M | $1.1B | $1.3B | $1.3B | $1.6B | $717M | $302M | $199M | $67M | $38M |
| Cash & Cash Equivalents | $94M | $143M | $100M | $312M | $81M | $108M | $588M | $9M | $3M | $31M | $5M |
| Total Liabilities | $113M | $284M | $530M | $645M | $704M | $800M | $75M | $75M | $63M | $67M | $14M |
| Total Debt (Short + Long-Term) | $2M | $2M | $2M | $3M | $3M | $2M | $3M | $3M | $2M | $0M | $0M |
| Total Shareholders' Equity | $562M | $434M | $562M | $660M | $565M | $782M | $642M | $227M | $137M | $0M | $24M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive ARVN viewer.
About TickerBase · Data methodology & sources · Privacy · Terms